JNJ-90009530
Phase 1Small molecule
Johnson & JohnsonJNJ-90009530 is one of 2 small molecule programs targeting Relapsed or Refractory B Cell Non-Hodgkin Lymphoma. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
1
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1 competitor in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
#DrugCompanyPhaseTrials
1B019
SShanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.
Phase 1
JNJ-90009530
Johnson & JohnsonPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for JNJ-90009530. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company